Service · 01
Educational Materials & CME
In-depth educational guides, slide decks, and clinician modules detailing complex mechanisms of action and trial data summaries.
REQUEST BRIEF
PharmD-Led Medical Communications
Evidence-based medical writing that bridges science and clinical practice.
Delivering strictly compliant, deeply researched cardiometabolic content for pharmaceutical leaders, medical device innovators, and healthcare organizations.
VOL · 01EST · 2024ISSN · CMW
GLP-1 RECEPTOR AGONISTSHEART FAILURE PROTOCOLS (HFREF / HFPEF)ANTICOAGULATION MANAGEMENTSGLT2 INHIBITORSCME CONTENTPEER-REVIEWED PRECISIONPHARMD EXPERTISEGLP-1 RECEPTOR AGONISTSHEART FAILURE PROTOCOLS (HFREF / HFPEF)ANTICOAGULATION MANAGEMENTSGLT2 INHIBITORSCME CONTENTPEER-REVIEWED PRECISIONPHARMD EXPERTISE
§ 01About & Clinical Expertise
Fig. 01 · Editorial DeskDOI · 10.CMW/01
Rooted in Clinical Practice, Driven by Evidence
Led by Kaley Mooney, PharmD — a licensed pharmacist specializing in cardiometabolic health. CardioMet Write translates complex clinical data into impactful, audience-tailored medical communications, whether addressing expert clinicians or empowered patients.
PharmD
Clinical Doctorate
0+
Years in Cardiometabolic Focus
0%
Evidence-Based Rigor
Compliant
Industry Standard Guidance
§ 02Core Services
Specialized Medical Writing Services
Four disciplines, one editorial standard. Each deliverable is grounded in primary literature, cited to peer-reviewed sources, and reviewed for regulatory compliance.
Service · 02
Practical Clinical Guides
Actionable protocols on GLP-1s, heart failure management (HFrEF / HFpEF), and anticoagulation bridging (DOACs, warfarin).
REQUEST BRIEF
Service · 03
Marketing & Promotional Collateral
Strictly compliant white papers, sales training materials, product brochures, and promotional slide decks for cardiometabolic therapeutics.
REQUEST BRIEF
Service · 04
Nutraceutical & Supplement Reviews
Rigorous, evidence-based reviews on omega-3s, CoQ10, berberine, and lifestyle interventions backed by clinical citations.
REQUEST BRIEF
§ 03Therapeutic Focus & Portfolio
Therapeutic Depth & Published Research
Medications & Therapeutics
GLP-1 RAs (semaglutide, tirzepatide), SGLT2i, PCSK9i, and beta-blockers.
Cardiovascular Protocols
Heart failure management pathways, anticoagulation dosing, and periprocedural care.
Evidence Evaluation
Literature reviews, meta-analysis summaries, and clinical trial breakdowns.
§ 04Selected Publications
Peer-reviewed selections
№ 01JAPHA · Research ArticleJournal of the American Pharmacists Association2024№ 02JAPHA · Clinical ArticleEvidence Analysis in Pharmacy Practice2024№ 03JAPHA · Published ResearchTherapeutic Guidelines Breakdown2022№ 04Editorial FeatureThe Doc Is In — Article Series2024№ 05Sample Deliverable · PDFCardiometabolic Writing Sample (PDF Document)PDF
§ 05Field Endorsements
Trusted by Healthcare Leaders
Hover any card to focus. Motion pauses in accordance with the reader.
"The accuracy and PharmD-level depth of the deliverables were beyond anything our team had worked with previously. Every citation held up to full internal review."
VP, Medical Affairs
Cardiometabolic Therapeutics Group
"Turned around a full CME module in half the timeline of our usual writers — and it passed compliance on first pass. That's rare."
CME Director
National Continuing Education Institute
"Kaley translates complex trial data into content our sales specialists can confidently use in the field. Compliant, precise, and clinically credible."
Clinical Brand Manager
Global Pharma · Diabetes Portfolio
"For an early-stage biotech, having a PharmD write our white papers gave the science instant authority. Investors and clinicians both took notice."
Founder & CSO
Series A Cardiovascular Biotech
"The accuracy and PharmD-level depth of the deliverables were beyond anything our team had worked with previously. Every citation held up to full internal review."
VP, Medical Affairs
Cardiometabolic Therapeutics Group
"Turned around a full CME module in half the timeline of our usual writers — and it passed compliance on first pass. That's rare."
CME Director
National Continuing Education Institute
"Kaley translates complex trial data into content our sales specialists can confidently use in the field. Compliant, precise, and clinically credible."
Clinical Brand Manager
Global Pharma · Diabetes Portfolio
"For an early-stage biotech, having a PharmD write our white papers gave the science instant authority. Investors and clinicians both took notice."
Founder & CSO
Series A Cardiovascular Biotech
Questions & Answers
Frequently Asked Questions
A short field guide to how CardioMet Write operates — from scope and therapeutic depth to engagement structure.
A PharmD brings deep, working knowledge of pharmacology, clinical trial design, and regulatory nuance — so complex mechanisms, endpoints, and label language don't require extensive onboarding or heavy editorial correction.
Primary focus is cardiometabolic health — GLP-1 receptor agonists, heart failure (HFrEF / HFpEF), anticoagulation, diabetes and lipid management — with broader capability across general medical communications.
CME slide decks, white papers, educational monographs, clinical protocols, promotional collateral, evidence reviews, patient education, and clinician-facing summaries — each grounded in primary literature.
Flexible engagement models: per-project deliverables with fixed scope, ongoing monthly retainers for teams with continuous needs, and hourly consultation for review, editing, or strategic input.
Next Chapter
Ready to elevate your medical communications with clinical precision?
§ 06Contact & Inquiry
Initiate a Project Collaboration
Direct Correspondence
Kaley Mooney, PharmD
Founder & Lead Medical Writer
- Emailkaley.wolff@yahoo.com
- Direct319 · 415 · 0812
- Office269 · 248 · 1509
- LinkedInin/kaley-mooney-pharmd
Schedule
Book a 30-minute consultCalendar Slot →